Drug Type Monoclonal antibody |
Synonyms Shirukumabu, Sirukumab (genetical recombination) (JAN), Sirukumab (USAN) + [3] |
Target |
Action inhibitors |
Mechanism IL-6 inhibitors(Interleukin-6 inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization |
Drug Highest PhaseDiscontinuedNDA/BLA |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Polymyalgia Rheumatica | Phase 3 | - | 15 Mar 2018 | |
Giant Cell Arteritis | Phase 3 | United States | 16 Oct 2015 | |
Giant Cell Arteritis | Phase 3 | Australia | 16 Oct 2015 | |
Giant Cell Arteritis | Phase 3 | Belgium | 16 Oct 2015 | |
Giant Cell Arteritis | Phase 3 | Bulgaria | 16 Oct 2015 | |
Giant Cell Arteritis | Phase 3 | France | 16 Oct 2015 | |
Giant Cell Arteritis | Phase 3 | Germany | 16 Oct 2015 | |
Giant Cell Arteritis | Phase 3 | Hungary | 16 Oct 2015 | |
Giant Cell Arteritis | Phase 3 | Italy | 16 Oct 2015 | |
Giant Cell Arteritis | Phase 3 | Netherlands | 16 Oct 2015 |
Phase 2 | 212 | (Sirukumab + SOC) | jnfwbsimkw(qdawlmsozd) = tbkkxgfoye jrguhscrev (vnzoihjqtu, eysptprqgd - osayqsykzc) View more | - | 21 Jun 2022 | ||
Placebo (Placebo + SOC) | jnfwbsimkw(qdawlmsozd) = uxpdhbkruv jrguhscrev (vnzoihjqtu, xrsrkmelkd - wzerprclur) View more | ||||||
Phase 3 | 161 | pvuohbwnse(cegnjsphgt) = lpuyhypker tjtqucdqah (rlosngjvtj ) | Positive | 01 Dec 2020 | |||
Placebo | pvuohbwnse(cegnjsphgt) = hlpmcdqdzw tjtqucdqah (rlosngjvtj ) | ||||||
Phase 2 | 193 | Placebo | ecbbpmmwlj(tlndxlzxng) = tyefmdfzwf hmreyxfakg (rvhpnjaoxx, 1.43) View more | - | 11 Jun 2019 | ||
Phase 3 | 1,820 | Placebo (Placebo to 50 mg q4w Due to EE/LE/CO) | ovvwxvljqm = sbtydippse zkmvtbtnmk (yewrkbiogw, xeqcorehff - qhxmqpdzdp) View more | - | 06 May 2019 | ||
Placebo (Placebo to 100 mg q2w Due to EE/LE/CO) | ovvwxvljqm = fcxkzcoszm zkmvtbtnmk (yewrkbiogw, aqsppaxezv - qkdccxajni) View more | ||||||
Phase 3 | - | kjyxxykypc(qyazueptuj) = vcffrmshmv diogedysxp (uqszojyksz ) | Positive | 01 May 2018 | |||
kjyxxykypc(qyazueptuj) = kypqwnnogi diogedysxp (uqszojyksz ) | |||||||
Phase 3 | 122 | (50 mg once every 4 weeks) | dyvlkfwsdl(qhuwwiakxp) = gqidhirjof ymdxrmsvdm (lopbdzzuyb ) | Positive | 07 Mar 2018 | ||
(100 mg once every 2 weeks) | dyvlkfwsdl(qhuwwiakxp) = jwhuyvydza ymdxrmsvdm (lopbdzzuyb ) | ||||||
Phase 3 | 1,670 | dtahhwnugz = mibkkevgna ohznapqzuq (ipyavbnxuw, nnmsqkdquv - yepbnakuro) View more | - | 11 Jan 2018 | |||
Phase 3 | 1,670 | Sirukumab 100mg every 2 weeks | qebtarxpky(mnckgxooxu) = injxodqatm hdibzvgqql (upondynrnh ) | Positive | 01 Dec 2017 | ||
Sirukumab 50mg every 4 weeks | qebtarxpky(mnckgxooxu) = dmoadqppme hdibzvgqql (upondynrnh ) | ||||||
Not Applicable | - | Biological DMARDs | vkpnwiutvj(thzgqzboyz) = itfopvxynv idnxtunijl (dmlgxdamql, [-0.6 - -0.08]) | Positive | 06 Nov 2017 | ||
Phase 3 | 559 | (Adalimumab 40 mg) | msnsbctcxo(krrixmwynq) = vkjiqplrlx knxmvaarjy (qzrmdplxae, 0.851) View more | - | 14 Sep 2017 | ||
(Sirukumab 50 mg) | msnsbctcxo(krrixmwynq) = ayshhlizsl knxmvaarjy (qzrmdplxae, 0.881) View more |